In the NewsJuly 20, 2025For infectious disease, plasma microbial cf-DNA testingJuly 19, 2025The BioHub - S2 Ep56 - Alec Ford & Stacy Solorio - KariusJune 3, 2025An Infectious Enthusiasm for AIMay 1, 2025Pulmonary Precision: Karius Launches Metagenomic Test for Lung InfectionsJanuary 15, 2025Meeting the Dream Makers Hear from the visionaries leading SoftBank Group portfolio companies shaping the future of medicine and health.December 20, 2024AI-Powered Blood Tests: Transforming Disease DetectionLoad morePress ReleasesApril 29, 2025Karius Launches Karius Focus™ | BAL: A Comprehensive and Timely Solution for Diagnosis and Management of Suspected Infectious Pneumonia and Other Lung Infections Among Immunocompromised PatientsAugust 8, 2024Karius Secures BARDA Contract to Expand Agnostic Detection of PathogensMay 16, 2024Karius Test® Receives FDA Breakthrough Device Designation to Aid in the Diagnosis of Infectious DiseaseMay 2, 2024Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance CrisisOctober 10, 2023Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood CancerAugust 10, 2023Karius Inc. Adds Dr. Norman Sharpless, Former National Cancer Institute Head, and Elizabeth O’Farrell, Eli Lilly Veteran, to its Board of Directors
January 15, 2025Meeting the Dream Makers Hear from the visionaries leading SoftBank Group portfolio companies shaping the future of medicine and health.